Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300477 | 1.00 | L3MBTL1 (0.40) | L3MBTL1CYP11B1CYP11B2HPGDALDH1A1 | |
| SCHEMBL2086904 | 0.84 | MEN1 (0.38) | CYP11B1CYP11B2HPGDALDH1A1KMT2A | |
| SCHEMBL2086908 | 0.84 | MEN1 (0.38) | CYP11B1CYP11B2HPGDALDH1A1KMT2A | |
| SCHEMBL21858958 | 0.81 | NPSR1 (0.42) | L3MBTL1HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL14698346 | 0.81 | CYP11B1 (0.47) | L3MBTL1CYP11B1CYP11B2HPGDALDH1A1 | |
| SCHEMBL21858959 | 0.81 | NPSR1 (0.42) | L3MBTL1HPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL15868733 | 0.81 | CYP11B1 (0.47) | L3MBTL1CYP11B1CYP11B2HPGDALDH1A1 | |
| SCHEMBL22400089 | 0.81 | HPGD (0.37) | CYP11B1CYP11B2HPGDALDH1A1KMT2A | |
| SCHEMBL22118240 | 0.79 | NPSR1 (0.39) | CYP11B1CYP11B2HPGDALDH1A1KMT2A | |
| SCHEMBL12646759 | 0.79 | NPSR1 (0.39) | CYP11B1CYP11B2HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | L3MBTL1 1224/4885CYP11B1 2508/4885CYP11B2 3189/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | L3MBTL1 1224/4885CYP11B1 2508/4885CYP11B2 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.